BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 9694728)

  • 1. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
    Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; Gordon MY
    Blood; 1998 Aug; 92(4):1390-6. PubMed ID: 9694728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.
    Verstegen MM; Cornelissen JJ; Terpstra W; Wagemaker G; Wognum AW
    Leukemia; 1999 Apr; 13(4):618-28. PubMed ID: 10214871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engraftment of chronic myeloid leukemia in SCID mice.
    Hoyle CF; Negrin RS
    Hematol Oncol; 1998 Sep; 16(3):87-100. PubMed ID: 10235067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation.
    Dazzi F; Hasserjian R; Gordon MY; Boecklin F; Cotter F; Corbo M; Capelli D; Goldman JM
    Hematol J; 2000; 1(5):307-15. PubMed ID: 11920208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
    Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C
    Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis.
    Sirard C; Lapidot T; Vormoor J; Cashman JD; Doedens M; Murdoch B; Jamal N; Messner H; Addey L; Minden M; Laraya P; Keating A; Eaves A; Lansdorp PM; Eaves CJ; Dick JE
    Blood; 1996 Feb; 87(4):1539-48. PubMed ID: 8608245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
    Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
    Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
    Koschmieder S; Göttgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS
    Blood; 2005 Jan; 105(1):324-34. PubMed ID: 15331442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propagation of human blastic myeloid leukemias in the SCID mouse.
    Sawyers CL; Gishizky ML; Quan S; Golde DW; Witte ON
    Blood; 1992 Apr; 79(8):2089-98. PubMed ID: 1562735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
    Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase.
    Wang JC; Lapidot T; Cashman JD; Doedens M; Addy L; Sutherland DR; Nayar R; Laraya P; Minden M; Keating A; Eaves AC; Eaves CJ; Dick JE
    Blood; 1998 Apr; 91(7):2406-14. PubMed ID: 9516140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
    Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
    Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
    Askmyr M; Ågerstam H; Lilljebjörn H; Hansen N; Karlsson C; von Palffy S; Landberg N; Högberg C; Lassen C; Rissler M; Richter J; Ehinger M; Järås M; Fioretos T
    Blood Cancer J; 2014 Dec; 4(12):e269. PubMed ID: 25501026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
    Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.